Generic drugs

Global Generic Inhalation and Nasal Spray Market Expected to Reach Over $ 10 Billion by 2026 –

DUBLIN – (COMMERCIAL THREAD) – The report “Generic Inhalation Drugs and Nasal Sprays Market Research Report by Indication, Age Group, Class, Route, Distribution Channel and Region – Global Forecast to 2026 – Cumulative Impact of COVID -19 “has been added to offer.

The global generic inhalation and nasal spray market size was estimated to be USD 6,392.52 million in 2020, is expected to reach USD 6,879.55 million in 2021, and is expected to grow at a CAGR of 7.95% to reach 10,119 , 95 million USD by 2026.

Market statistics

The report provides market size and forecast in five major currencies: USD, EUR GBP, JPY, and AUD. It helps organizational leaders make better decisions when currency data is readily available. In this report, the years 2018 and 2019 are considered as historical years, 2020 as the base year, 2021 as the estimated year and the years 2022 to 2026 are considered as the forecast period.

Market segmentation and coverage

This research report categorizes Generic Inhalation Drugs and Nasal Sprays to forecast revenue and analyze trends in each of the following submarkets:

  • Based on the indication, the market has been investigated for allergic rhinitis, asthma and COPD.

  • Based on age group, the market has been researched among adults, children 2-5 years old, and children 6-12 years old.

  • Based on the class, the market has been studied for allergy blockers, anticholinergics, antihistamines, decongestants, mast cell inhibitors, and nasal steroids.

  • Based on Route, the market has been investigated for inhalation, nasal spray, and tropical lotion.

  • Based on the distribution channel, the market has been studied in hospital medical stores, online pharmacies and retail pharmacies.

  • Based on the region, the market has been studied in the Americas, Asia-Pacific and Europe, Middle East and Africa. The Americas are studied in more detail in Argentina, Brazil, Canada, Mexico and the United States. The United States is studied in more detail in California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. Asia-Pacific is further explored in Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, the Middle East and Africa are studied in more detail in France, Germany, Italy, the Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates and United Kingdom.

Companies mentioned

  • Allergan plc

  • Altaire Pharmaceuticals inc.

  • Beximco Pharmaceuticals Ltd.

  • Catalent Pharma Solutions

  • Cipla Limited

  • Hikma Pharmaceuticals PLC

  • Mylan NV

  • Navajo Manufacturing Company Inc.

  • Pharmaceutical company Nephron

  • Perrigo Company plc

  • Preferred Pharmaceuticals Inc.

  • Sandoz International GmbH

  • Sheffield Pharmaceuticals LLC

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

Cumulative impact of COVID-19

COVID-19 is an incomparable global public health emergency that has affected nearly all industries, and the long-term effects are expected to impact the growth of the industry during the forecast period. The analyst’s ongoing research is amplifying their research framework to ensure the inclusion of the underlying issues of COVID-19 and potential avenues to follow. The report provides insight on COVID-19 given changes in consumer behavior and demand, purchasing patterns, supply chain diversion, dynamics of current market forces, and significant government interventions. . The updated study provides information, analysis, estimates and forecasts, considering the impact of COVID-19 on the market.

Competitive strategic window

The Competitive Strategy Window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for suppliers to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to continue the expansion and growth of the business during a forecast period.

FPNV positioning matrix

The FPNV Positioning Matrix assesses and ranks vendors in the Generic Inhalation and Nasal Spray market based on business strategy (company growth, industry coverage, financial viability, and channel support) and product satisfaction (value for money, ease of use, product features) and customer support) which helps businesses make better decisions and better understand the competitive landscape.

Market share analysis

The market share analysis offers the analysis of the suppliers considering their contribution to the overall market. It provides the idea of ​​its revenue generation in the overall market compared to other space providers. It provides insight into the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of the suppliers for the base year. It reveals the characteristics of the market in terms of traits of accumulation, fragmentation, dominance and fusion.

Competitive scenario

The competitive scenario provides a outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section delivers valuable insights at different stages while staying up to date with the business and engaging stakeholders in the economic debate. The competitive scenario represents press releases or news from companies categorized as M&A, Agreement, Collaboration and Partnership, New Product Launch and Improvement, Investment and Funding, and Reward, Recognition and Expansion. All the news gathered helps the supplier understand the market gaps and the strengths and weaknesses of the competitors, thus providing information to improve products and services.

Main topics covered:

1. Preface

1.1. Objectives of the study

1.2. Market segmentation and coverage

1.3. Years taken into account for the study

1.4. Currency and price

1.5. Language

1.6. Limits

1.7. Hypotheses

1.8. Stakeholders

2. Research methodology

3. Executive summary

4. Market overview

4.1. introduction

4.2. Cumulative impact of COVID-19

5. Market dynamics

5.1. introduction

5.2. Conductors

5.2.1. Low cost associated with generic prescription drugs

5.2.2. Increased prevalence of asthma and COPD disorders

5.2.3. High cost of health care in developed regions

5.3. Constraints

5.3.1. Strict regulations for generic drugs

5.4. Opportunities

5.4.1. Successful drug patents expire and FDA approvals increased

5.4.2. Trend towards generic drugs in developed countries due to rising cost of health care

5.5. Challenges

5.5.1. Pressure on prices due to the presence of several players in the segment

6. Generic Inhalation and Nasal Sprays Market, by Indication

6.1. introduction

6.2. Allergic rhinitis

6.3. Asthma

6.4. COPD

7. Generic Inhalation Nasal Spray Drugs Market, By Age Group

7.1. introduction

7.2. Adults

7.3. Children 2 to 5

7.4. Children 6 to 12

8. Generic Inhalation and Nasal Spray Drugs Market, By Class

8.1. introduction

8.2. Allergy blocker

8.3. Anticholinergic

8.4. Antihistamine

8.5. decongestant

8.6. Mast cell inhibitor

8.7. Nasal steroid

9. Generic inhalation and nasal sprays market, by road

9.1. introduction

9.2. Inhalation

9.3. Nasal spray

9.4. Tropical Lotion

10. Generic inhalation and nasal sprays market, by distribution channel

10.1. introduction

10.2. Hospital medical store

10.3. Online pharmacy

10.4. Retail pharmacy

11. America Generic Inhalation and Nasal Spray Market

12. Asia-Pacific Generic Inhalation and Nasal Spray Market

13. Europe, Middle East & Africa Generic Inhalation Drugs and Nasal Sprays Market

14. Competitive landscape

14.1. FPNV positioning matrix

14.1.1. Quadrants

14.1.2. Business strategy

14.1.3. Product satisfaction

14.2. Market ranking analysis

14.3. Market share analysis, by key player

14.4. Competitive scenario

14.4.1. Merger & Acquisition

14.4.2. Agreement, collaboration and partnership

14.4.3. New product launch and improvement

14.4.4. Investment and financing

14.4.5. Awards, recognition and expansion

15. Company usability profiles

For more information on this report, visit

Tags : drugs marketforecast periodgeneric drugshealth caremarket researchmarket sizeprescription drugspublic healthsupply chainunited states
Joan J. Dean

The author Joan J. Dean